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Fig. 1. Mucosal eosinophils may face several fates in vivo.
Black and grey arrows represent pathways for cell trac
and granule protein release, respectively. Without loosing
viability tissue eosinophils undergo piecemeal
degranulation (PMD). During active disease processes
many tissue eosinophils are ‘ultimately activated’ to
undergo eosinophil cytolysis (ECL). Viable tissue
eosinophils migrate into the airway lumen. The luminal
eosinophils are further cleared through cytolysis,
mucociliary clearance and apoptosis. However, data are
scarce on the occurrence of apoptotic eosinophils in the
airway tissue.
ABSTRACTS 1263salt sodium arsenite which presents not only a tumour
enhancer but also a potent inducer of stress responses.
Sodium arsenite is known to disturb the oxygen metabolism
in mitochondria which are major sites of reactive oxygen
production. Apart from this sodium arsenite also regulates
intracellular glutathione levels. There was a significant
increase in the rate of eosinophil apoptosis with low
concentrations of sodium arsenite whereas high concentra-
tions showed rates of apoptosis similar to control medium.
Investigating the role of intracellular oxidants by flow
cytometry we found that while inducing apoptosis sodium
arsenite more than anti-Fas mAb resulted in a significant
dose-dependent prouction of intracellular H2O2 (4). In
contrast, the extracellular release of spontaneous, receptor-
dependent (fMLP), and receptor independent stimulation
(by PMA) of the extracellular release of superoxide anion
decreased after stimulation with sodium arsenite or anti-
Fas mAb. Co-incubation experiments demonstrated that
arsenite as well as anti-Fas mAb induced apoptosis can be
nearly completely prevented by antioxidants such as
glutathione, and N-acetylcysteine but not dimethyl sulph-
oxide or taurine. Moreover, glutathione and N-acetylcys-
teine were able to significantly delay spontaneous apoptosis
in unstimulated eosinophils. Taken together these data
point to an important role of oxygen-dependent mechan-
isms and particularly of a thiol-sensitive redox system in the
regulation of eosinophil survival and apoptosis. We
propose that the level of intracellular glutathione may be
responsible for the ability of the cell to maintain an
appropriate oxidant–antioxidant balance deciding
between survival and apoptosis. Accordingly, we have
evidence for an increased intracellular glutathione content
in atopic dermatitis eosinophils which may cause the
significant delay in apoptosis and the resistance to anti-
Fas mAb when compared to eosinophils from non-atopic
donors. Further solving the puzzle of inhibited eosinophil
apoptosis will not only improve our understanding of
atopic disorders but may also have major therapeutic
implications.
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Extensive research in vitro has produced detailed schemes of
molecular pathways controlling activation and death of
cultured eosinophil phenotypes. This molecular informa-
tion may now be contrasted by the fact that several key
questions on gross eosinophil events in vivo remain
unresolved. As exemplified below, there is an urgent need
for further demonstration and confirmation in vivo of major
modes of activation and demise of tissue eosinophils.
Once recruited to the mucosa eosinophils may be
activated to release their granule products in several distinct
ways (Fig. 1). Piecemeal degranulation (PMD) has been
described in vivo in several eosinophilic conditions. Another
event, eosinophil cytolysis (ECL), leads to extensive granule
protein release. ECL appears to be common in diseased
tissues in vivo but almost nothing is known, as yet, about its
molecular regulation. In contrast, eosinophil apoptosis
belongs to the ‘cutting edge’ in vitro research lines.
1264 ABSTRACTSHowever, convincing evidence to support a functional role
of eosinophil apoptosis in vivo is scarce.
Piecemeal degranulation (PMD)
The possibility of a long-term and finely tuned eosinophil
degranulation is provided by piecemeal degranulation
(PMD). Detailed ultrastructural studies have revealed that
during this process small portions of the granule content
are gradually released through transport vesicles (1).
Mucosal eosinophils undergoing PMD have been depicted
in several eosinophilic conditions. However, it is not until
recently that quantitative data on its occurrence and extent
have become available. In a recent study, examining
biopsies from patients with active allergic rhinitis, it was
demonstrated that resting eosinophils were absent and all
viable eosinophils exhibited signs of PMD (2). No
correlation was observed between the degree of eosinophilia
and extent of PMD. Indeed, a very low index of PMD may
be present in tissues exhibiting an extensive eosinophilia,
for example in inflammatory bowel diseases (Erjefa¨lt et al.,
unpublished observations). Studies are now warranted to
establish the degree of PMD in different eosinophilic
conditions (including animal models) and to explore
correlations between the extent of PMD and disease
severity. Unfortunately, so far the search for human-like
PMD and ECL in the commonly used mouse models of
asthma and rhinitis have been unsuccessful (3).
Eosinophil cytolysis (ECL)
Eosinophil cytolysis was recently forwarded as a primary
effector mechanism by which eosinophils affect their
surroundings (4). During ECL eosinophils are stimulated
to die through cytolysis resulting in chromatolysis, rupture
of the cell membrane and spilling of the granules into the
surrounding tissue. As such ECL is a noxious form of cell
death, that is distinct from apoptosis, and that results in
rapid and complete release of the cell content. Using
tracheal whole-mount techniques a correlation between
ECL and areas of epithelial damage has been observed in
allergen-exposed guinea-pigs (5). ECL and its produce,
clusters of free eosinophil granules, have also been
described in asthma, rhinitis, nasal polyposis, atopic
dermatitis and various IBD conditions (4). Furthermore,
numerous reports have described extensive ECL close to
parasites in skin biopsies from patients undergoing
antihelmintic chemotherapy. Despite evident examples,
ECL has not until recently been included in general
discussions on eosinophil mechanisms. In part this fact
may derive from the common belief that eosinophils
cytolysis would be a secondary event to extensive PMD.
However, novel data emanating from studies of human
mucosal eosinophils in vivo have demonstrated that ECL
may take place foremost in eosinophils exhibiting little or
no signs of PMD. This finding indicates that ECL and
PMD are distinct and independent mechanisms by which
eosinophils release their granule content (2,6).Currently almost nothing is known regarding the
molecular regulation of ECL. Studies in vitro have
demonstrated that purified blood eosinophils undergo
ECL as a result of MAC-1(CD18/CD11b)-dependent
binding of eosinophils to sIgA-coated Sepharose beads
(7–8). Importantly, in this model the extent of PMD was
not elevated in cytolytic eosinophils (8). Further studies are
now warranted to unravel the cellular signals involved in
ECL. Recent findings in cells other than eosinophils
strongly suggest that controlled and ‘programmed’ cell
death may not be exclusive to apoptosis. For example,
stimulation of the FAS receptor and TNF-R1 may lead to
either apoptosis or ‘necrosis’ in mouse fibrosarcoma cells or
human T cells. At the current state of knowledge it can not
be excluded that the execution of ECL is well-controlled
and that ECL and apoptosis share common pathways.
Indeed, the entire field of biological and pharmacological
control of ECL is yet to be explored.
Apoptosis
Apoptosis of tissue eosinophils has been suggested to be a
major mechanism for the resolution of an eosinophilic
inflammation, for example during allergen avoidance or
anti-inflammatory treatment. The fact that cultured eosi-
nophils spontaneously undergo apoptosis has provided
accessible test systems for detailed molecular studies. In
these models survival factors, such as IL-5 and GM-CSF,
protect eosinophils from apoptosis; steroids effectively
inhibit this effect. A pro-apoptotic effect has thus been
forwarded as a major modus operandi of glucocorticoster-
oids. However, actual in vivo evidence to support this
notion is scarce.
Although several recent publications claim to demon-
strate apoptotic eosinophils in inflamed and steroid-treated
tissues the provided pictorial evidence of apoptotic
eosinophils may not well support this claim. Furthermore,
the frequently cited reports demonstrating that apoptotic
eosinophils occur in airway luminal samples would merely
support the possibility that luminal entry of viable
eosinophils is an important clearance mechanism (see
Fig. 1). Little discussed is also the fact that several studies
have failed to find apoptotic eosinophils in eosinophil-rich
tissues, even during steroid treatment. Further studies
examining the extent and kinetics of eosinophil apoptosis
in vivo, as well as alternative leukocyte clearance mechan-
isms, are clearly needed. One such mechanism that has been
ignored in this field of research is lumenal entry (Fig. 1).
Indeed, eosinophilic inflammation might in part be resolved
through an ecient and silent escape of viable eosinophils
into the airway lumen.
Summary
Despite the fact that the modes of activation and fate of
eosinophils would determine the role of these leukocytes in
health and disease major degranulation and clearance
mechanisms in vivo have remained largely unexplored.
ABSTRACTS 1265Increasingly, ultrastructural analysis emerges as a potent
tool for detailed quantification of PMD, ECL and
apoptosis in vivo. Recent ultrastructural observations thus
indicate that different eosinophilic conditions may be
characterized by distinct degranulation and clearance
patterns. Importantly, research in this area would also
provide essential information as to which aspects of
eosinophil activation and demise should be mimicked in
our in vitro test systems.
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